AstraZeneca Receives $205M Army COVID-19 Antibody Drug Order

The U.S. Army has reserved at least 100,000 doses of AstraZeneca’s AZD7442, a long-acting antibody product designed to prevent COVID-19 infection or treat the coronavirus disease, through a $204.9 million contract modification.

The service branch obligated the full amount using its fiscal 2021 research, development, test and evaluation funds, the Department of Defense said Tuesday.

Contract work will take place in Wilmington, Delaware, through Dec. 31.

AstraZeneca licensed the AZD7442 combination therapy of two long-acting antibodies from the Vanderbilt University Medical Center in Nashville, Tennessee, last year and engineered the drug using the company’s proprietary half-life extension technology.

A Phase III clinical trial is underway to evaluate the efficacy and safety of the LAAB combo product as a treatment for non-hospitalized COVID-19 patients.

Video of the Day

GovCon Wire Logo

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings about Contract Awards

Related Articles

The Ultimate Guide to Winning Government Contracts Let us show you how top executives are winning so you can replicate it